• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Talicia (omeprazole magnesium, amoxicillin and rifabutin)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Talicia (omeprazole magnesium, amoxicillin and rifabutin)

  • Profile

Profile

Contact Information

Contact: Redhill Biopharma
Website: https://www.talicia.com/

Currently Enrolling Trials

    Show More

    General Information

    Talicia is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (PPI) (omeprazole).

    Talicia is specifically indicated for the treatment of Helicobacter pylori infection in adults.

    Talicia is supplied as a capsule for oral administration. 

    To reduce the development of drug-resistant bacteria and maintain the effectiveness of Talicia and other antibacterial drugs, Talicia should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

    Administer four (4) Talicia capsules every 8 hours for 14 days with food. Patients should swallow the Talicia capsules whole, with a full glass of water (8 ounces). Each dose (4 capsules) of Talicia includes rifabutin 50 mg, amoxicillin 1,000 mg and omeprazole 40 mg. Do not crush or chew Talicia capsules. Do not take Talicia with alcohol. If a dose is missed, patients should continue the normal dosing schedule until the medication is completed. Do not take two doses at one time to make up for a missed dose.

    Mechanism of Action

    Talicia is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (PPI) (omeprazole).

     Amoxicillin acts through the inhibition of cell wall biosynthesis that leads to the death of bacteria.  Rifabutin inhibits DNA-dependent RNA polymerase in susceptible microorganisms but not in mammalian cells. Resistance to amoxicillin is mediated primarily through beta-lactamases that cleave the beta-lactam ring of amoxicillin, rendering it inactive.  Resistance to rifabutin occurs through mutations in the DNA-dependent RNA polymerase.  

    Side Effects

    Adverse effects associated with the use of Talicia may include, but are not limited to, the following:

    • diarrhea
    • headache
    • nausea
    • abdominal pain
    • chromaturia
    • rash
    • dyspepsia
    • oropharyngeal pain
    • vomiting
    • vulvovaginal candidiasis

    Clinical Trial Results

    The FDA approval of Talicia was based, in part, on the results of two positive Phase 3 studies in the U.S. for the treatment of H. pylori-positive adult patients complaining of epigastric pain and/or discomfort.

    Study 1 was was a a randomized, double-blind, controlled study in treatment-naïve H. pylori-positive adult patients complaining of epigastric pain/discomfort. H. pylori infection at baseline was defined as positive by 13C urea breath test (UBT) and follow-up upper endoscopy (culture, histology, or Campylobacter-like organism test). Patients were randomized 1:1 to Talicia or control (total daily dose of amoxicillin 3000 mg and omeprazole 120 mg) administered for 14 consecutive days. The trial was performed in the U.S and designed to evaluate the added contribution of rifabutin to the Talicia triple combination. H. pylori eradication was confirmed with a negative 13C UBT or fecal antigen test performed ≥28 days posttherapy. Patients with negative test results were considered treatment successes. Patients who tested positive for H. pylori infection were considered treatment failures, and patients with indeterminate, not assessable, or missing results from the test of cure visits underwent a repeat 13C UBT test. Persistent indeterminate results and patients without any 13C UBT or fecal antigen test after baseline were considered as treatment failures. The difference in response rates between Talicia and the control was 26.1%.

    Study 2 was a randomized, double-blind, placebo-controlled study of Talicia in H. pylori-positive adult patients complaining of epigastric pain/discomfort was performed in the U.S. and provided supportive evidence for the efficacy of Talicia for the treatment of H. pylori infection; 77 patients taking Talicia and 41 patients taking placebo were included in the ITT population, with an eradication rate of 76.6% the Talicia-treated patients compared to 2.4% for the placebo-treated patients.  Eleven patients in the Talicia arm and four patients in the placebo arm were classified as treatment failures due to missing 13C UBT results at the test-of-cure visit.

    Approval Date: 2019-11-01
    Company Name: Redhill Biopharma
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • SurveywBlueBackground-360x240.png

      Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

    • TrendsInsights2023-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Two

    • TimeMoneyEffort-360x240.png

      Time is Money and So Is Effort, Budgeting Experts Say

    • TrendsInsights2023A-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Three

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing